6.
Ichim G, Tait S
. A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer. 2016; 16(8):539-48.
DOI: 10.1038/nrc.2016.58.
View
7.
Steinway S, G T Zanudo J, Ding W, Rountree C, Feith D, Loughran Jr T
. Network modeling of TGFβ signaling in hepatocellular carcinoma epithelial-to-mesenchymal transition reveals joint sonic hedgehog and Wnt pathway activation. Cancer Res. 2014; 74(21):5963-77.
PMC: 4851164.
DOI: 10.1158/0008-5472.CAN-14-0225.
View
8.
Montero J, Sarosiek K, DeAngelo J, Maertens O, Ryan J, Ercan D
. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015; 160(5):977-989.
PMC: 4391197.
DOI: 10.1016/j.cell.2015.01.042.
View
9.
Madrid L, Wang C, Guttridge D, Schottelius A, Baldwin Jr A, Mayo M
. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol. 2000; 20(5):1626-38.
PMC: 85346.
DOI: 10.1128/MCB.20.5.1626-1638.2000.
View
10.
Berraondo P, Sanmamed M, Ochoa M, Etxeberria I, Aznar M, Perez-Gracia J
. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018; 120(1):6-15.
PMC: 6325155.
DOI: 10.1038/s41416-018-0328-y.
View
11.
Chonghaile T, Sarosiek K, Vo T, Ryan J, Tammareddi A, Gaizo Moore V
. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011; 334(6059):1129-33.
PMC: 3280949.
DOI: 10.1126/science.1206727.
View
12.
Rayet B, Gelinas C
. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999; 18(49):6938-47.
DOI: 10.1038/sj.onc.1203221.
View
13.
Wajant H, Pfizenmaier K, Scheurich P
. Tumor necrosis factor signaling. Cell Death Differ. 2003; 10(1):45-65.
DOI: 10.1038/sj.cdd.4401189.
View
14.
G T Zanudo J, Steinway S, Albert R
. Discrete dynamic network modeling of oncogenic signaling: Mechanistic insights for personalized treatment of cancer. Curr Opin Syst Biol. 2020; 9:1-10.
PMC: 7487767.
DOI: 10.1016/j.coisb.2018.02.002.
View
15.
Dondelinger Y, Delanghe T, Rojas-Rivera D, Priem D, Delvaeye T, Bruggeman I
. MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death. Nat Cell Biol. 2017; 19(10):1237-1247.
DOI: 10.1038/ncb3608.
View
16.
Hanahan D, Weinberg R
. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74.
DOI: 10.1016/j.cell.2011.02.013.
View
17.
Totzke J, Gurbani D, Raphemot R, Hughes P, Bodoor K, Carlson D
. Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chem Biol. 2017; 24(8):1029-1039.e7.
PMC: 5576570.
DOI: 10.1016/j.chembiol.2017.07.011.
View
18.
Fumia H, Martins M
. Boolean network model for cancer pathways: predicting carcinogenesis and targeted therapy outcomes. PLoS One. 2013; 8(7):e69008.
PMC: 3724878.
DOI: 10.1371/journal.pone.0069008.
View
19.
Matveeva A, Fichtner M, McAllister K, McCann C, Sturrock M, Longley D
. Heterogeneous responses to low level death receptor activation are explained by random molecular assembly of the Caspase-8 activation platform. PLoS Comput Biol. 2019; 15(9):e1007374.
PMC: 6779275.
DOI: 10.1371/journal.pcbi.1007374.
View
20.
Tang D, Du W, Shekhtman L, Wang Y, Havlin S, Cao X
. Predictability of real temporal networks. Natl Sci Rev. 2021; 7(5):929-937.
PMC: 8288877.
DOI: 10.1093/nsr/nwaa015.
View